Filament Health Corp. Announces Non-Brokered Private Placement Unit Offering of Up To C$2,000,000 | Psychedelic Invest

Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical‐stage natural psychedelic drug development company, today announced that it intends to complete, subject to regulatory approval, a non-brokered private placement for gross proceeds of up to C$2,000,000 (the “Offering“). The Offering will be led by Negev Capital, a psychedelic medical intervention investment fund.

“We are thrilled to further our relationship with Negev to continue to advance Filament’s drug development platform,” said Benjamin Lightburn, Chief Executive Officer and Co‐Founder at Filament.

The Offering is a non-brokered private placement of up to 22,222,222 units (the “Units“) at a price of C$0.09 per Unit (the “Issue Price“), or other amount approved by the NEO Exchange, for gross proceeds of up to C$2,000,000. Each Unit will consist of one common share of the Company (a “Common Share“) and one common share purchase warrant (the “Warrants“). Each Warrant will be exercisable to acquire one Common Share for a period of 36 months following the closing date of the Offering at an exercise price of C$0.117, representing a 30% premium to the Issue Price, or other amount approved by the NEO Exchange.

Negev Capital, a psychedelic medical intervention investment fund that has made over 20 investments to date, is the lead investor of the Offering. Net proceeds from the Offering are expected to be used to recruit patients and initiate the Company’s Phase 2 Methamphetamine Use Disorder clinical trial which has already received FDA approval, as well as other general corporate purposes.

The Offering is subject to the approval of the NEO Exchange and the securities issued thereunder will be subject to a four month hold period under securities laws. The securities offered in the Offering have not been, nor will they be, registered under the Securities Act, or any state securities laws, and may not be offered or sold to, or for the account or benefit of, any person in the United States or any “U.S person”, as such term is defined in Regulation S under the Securities Act, absent registration or an applicable exemption from registration requirements. Offers and sales in the United States will be limited to institutional accredited investors. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

Filament is a natural psychedelic drug development company focused on the treatment of substance use disorders. Filament’s proprietary technology platform enables the discovery and delivery of botanical psychedelic medicines for clinical development. The Company is currently generating revenue by out-licensing its lead drug candidate, PEX010, to commercial partners. PEX010 is standardized to provide a precise dose of botanical psilocybin per oral capsule, and is currently being administered in phase 1 and 2 human clinical trials approved by U.S. Food and Drug Administration (“FDA“) and Health Canada. It is currently being studied in 15 clinical trials in North America and Europe via Filament’s network of academic and research institutions for conditions including alcohol use disorder, treatment resistant depression, opioid tapering, and chronic pain. All of the trials are being conducted under the authorization of the applicable governing authority, including, but not limited to, the US Food and Drug Administration, Health Canada and European Medicines Agency. The Company believes that, as a botanical drug, PEX010 offers intellectual property benefits versus synthetic drugs due to its complex active pharmaceutical ingredient, as well as a more rapid path into clinical development. Filament is actively pursuing early access schemes around the world and has supplied dozens of Canadian patients via the Health Canada Special Access Program.